<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0"><channel><title>Individual feed for https://search.cnbc.com/rs/search/combinedcms/view.xml?partnerId=wrss01&amp;id=15839069</title><link>https://search.cnbc.com/rs/search/combinedcms/view.xml?partnerId=wrss01&amp;id=15839069</link><description>Individual feed output.</description><lastBuildDate>Fri, 23 Jan 2026 17:10:58 GMT</lastBuildDate><generator>PyRSS2Gen-1.1.0</generator><docs>http://blogs.law.harvard.edu/tech/rss</docs><item><title>Flocking to precious metal ETFs? Keep an eye out for these tax surprises</title><link>https://www.cnbc.com/2026/01/23/flocking-to-precious-metal-etfs-watch-for-these-tax-surprises.html</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture5.png</image_url><description>Precious metals are rallying, but investors who are buying into the trade could be in for some tax complexity.</description><pubDate>Fri, 23 Jan 2026 20:31:19 GMT</pubDate></item><item><title>Intel's likely to still move higher. Here's a 'no-cost' options strategy to play it</title><link>https://www.cnbc.com/2026/01/23/intels-likely-to-still-move-higher-heres-a-no-cost-options-strategy-to-play-it-.html</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture3.png</image_url><description>Intel is an essential name to the U.S. economy and the "Soprano-like" equity ownership by the government makes me want to own this company for the lon...</description><pubDate>Fri, 23 Jan 2026 16:56:59 GMT</pubDate></item><item><title>JPMorgan upgrades consumer goods stock on confidence in second-half acceleration</title><link>https://www.cnbc.com/2026/01/23/jpmorgan-upgrades-consumer-goods-stock-citing-expected-2h-acceleration.html</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture3.png</image_url><description>JPMorgan sees shares of Procter &amp; Gamble rising 11% from current levels.</description><pubDate>Fri, 23 Jan 2026 16:54:46 GMT</pubDate></item><item><title>Roth says this biopharma stock has room to run on drug momentum, upcoming trial catalysts</title><link>https://www.cnbc.com/2026/01/23/roth-says-this-biopharma-stock-has-room-to-run-on-drug-momentum-upcoming-trial-catalysts.html</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture5.png</image_url><description>Roth's $212 price target implies an additional upside of 32% for shares of Insmed, which have already rallied 160% in the last 12 months.</description><pubDate>Fri, 23 Jan 2026 16:52:22 GMT</pubDate></item><item><title>Intel’s earnings beat couldn’t offset a weaker-than-expected outlook. Here’s what analysts are saying</title><link>https://www.cnbc.com/2026/01/23/intels-earnings-beat-couldnt-offset-a-weaker-than-expected-outlook-heres-what-analysts-are-saying.html</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture9.png</image_url><description>For the most part, Wall Street analysts maintained a hold-equivalent rating on Intel after supply constraints weighed on the company's current-quarter...</description><pubDate>Fri, 23 Jan 2026 16:47:26 GMT</pubDate></item></channel></rss>